Neomorph.

A drug just entered a patient. The hard part started years earlier.

Somewhere in a clinic, a person with advanced kidney cancer receives the first dose of NEO-811. It is a small molecule, the kind you could fit thousands of into a grain of rice. It does not block the cancer protein. It does something stranger: it introduces that protein to the cell's own disposal crew and waits while the cell shreds it. This is the moment Neomorph was built for, and it is the easy part to describe. The hard part - the part that took six years, three pharma giants, and roughly $209 million - was convincing biology that a target everyone called "undruggable" was simply waiting for the right introduction.

Neomorph is a clinical-stage biotechnology company in San Diego with about 85 people and an unusually specific obsession: molecular glue degraders. Where most drugs work like a wad of gum jammed into a lock, Neomorph's molecules work like a matchmaker, sticking a disease-driving protein to one of the cell's E3 ubiquitin ligases - the enzymes that tag proteins for destruction. The protein gets marked as garbage. The cell does the rest. Then the drug moves on and does it again.

Eighty percent of the proteome shrugs off conventional drugs.

Here is the inconvenient truth the pharmaceutical industry has lived with for decades. Most drugs need a pocket - a deep, well-shaped groove on a protein where a molecule can wedge itself and gum up the works. The trouble is that the great majority of human proteins have no such pocket. They are smooth. Flat. Disorderly. The proteins that drive cancer, neurodegeneration, and rare disease are, with cruel frequency, exactly the smooth ones. The industry has a polite word for them: undruggable. It is less a scientific category than a confession.

Blocking a protein also has a math problem. To keep a target switched off, you generally need to keep the drug glued to it, which means high doses and constant occupancy. Degradation flips the logic. Destroy the protein once and the effect lasts until the cell makes more. Do it with a catalytic molecule and a little goes a long way. The idea is old. The execution is what nobody could reliably do.

The people who decoded thalidomide decided to weaponize it.

Molecular glues were, for years, a happy accident. Thalidomide and its descendants worked beautifully and nobody fully understood why - until a cluster of scientists worked out that these drugs glue a target protein to cereblon, part of a CRL4-CRBN ligase complex, marking it for degradation. Neomorph's scientific founders are a who's-who of that discovery. Eric Fischer helped solve the DDB1-CRBN-thalidomide structure published in Nature in 2014. Benjamin Ebert helped define how lenalidomide drives degradation, work published in Science the same year. Philip Chamberlain spent years at Celgene pioneering cereblon mechanisms. Scott Armstrong brought Dana-Farber's oncology depth.

In 2020, Deerfield Management assembled them into a company. The bet was not that molecular glues could work - thalidomide already proved that. The bet was that glues could be designed on purpose, systematically, against targets chosen in advance rather than stumbled upon. That is a much larger and riskier claim, and it is the one Neomorph staked its existence on.

A discovery engine, then a pipeline that comes out of it.

Neomorph's core asset is not a single drug. It is a factory for finding glues. The company says it has assembled the world's largest proprietary molecular glue target space, stitched together from novel degrons, custom glue chemistry libraries, an expansive portfolio of E3 ligases, and a stack of structural biology - cryo-EM, crystallography - feeding into high-throughput screening and machine learning. The point is to make serendipity repeatable. Out of that engine comes a pipeline.

Three pharma giants signed before the lead drug reached a patient.

Skepticism is the correct posture toward any biotech promising to drug the undruggable; the graveyard is full of them. So look at what independent parties were willing to pay. AbbVie, Novo Nordisk, and Biogen each committed to multi-target collaborations - the kind of deal a large pharma does not sign casually, because it ties up scientists and budget for years. The headline potential values are heavy on back-loaded milestones, as these deals always are, but the upfront commitments and the caliber of partner are hard to fake.

Make "undruggable" a temporary diagnosis.

Strip away the deal values and the platform language and Neomorph's mission is almost stubbornly simple: build medicines against the disease drivers that conventional drugs cannot touch. The targets it cares about are the ones that have humiliated the industry for decades - the smooth proteins behind certain cancers, neurodegenerative conditions, immune disorders, and rare diseases. The mission is not to invent a clever modality for its own sake. It is to turn a long list of "we can't" into a shorter one.

Why the next dose matters more than the first.

If degradation generalizes the way Neomorph is betting, the implications run past any single drug. A repeatable way to design glues would put a large slice of the human proteome back on the table - targets shelved for thirty years because nobody could find a pocket. That is the optimistic read. The honest read is that NEO-811 is one molecule in an early trial, milestone payments are promises rather than cash, and biology has humbled better-funded efforts. Both readings are true at once, which is exactly what makes the company worth watching rather than worth hyping.

Return to the clinic. The patient with kidney cancer has received the first dose of NEO-811. A few years ago, the protein it targets sat on the wrong side of the word "undruggable," and the only honest thing to say about it was nothing. Now there is a molecule, a trial, and a question with a real answer coming. Neomorph did not cure anything that afternoon. It did something narrower and harder to dismiss: it moved a target from the impossible column to the in-progress one. That is the whole job. The rest is data.

Dossier compiled from public sources // figures are approximate and milestone-dependent